QRxPharma Limited

Type: Company
Name: QRxPharma Limited
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

"We don't think we need new opioids": An exclusive interview with Andrew Kolodny

The Anesthetic and Analgesic Drug Products Advisory Committee of the FDA will meet on April 22, 2014 , to review the New Drug Application for Moxduo, also known as Q8003, an investigational new drug from QRxPharma. Moxduo IR is an opioid-opioid analgesic, ... [Published Examiner.com - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Hidden Australian Life Sciences Growth Stocks Revealed: Scott Power

SummaryThe limited pool of venture and development capital in Australia tends to make companies list at an earlier stage than in the U.S, which has its advantages and disadvantages. The better quality names in Australia are not having too much trouble ... [Published Seeking Alpha - Apr 17 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

FDA to consider morphine-oxycodone combo pill

Government health officials' concerns about acetaminophen-related liver damage have opened the door for sales of one non-abuse-deterrent opioid, and may help to put another dangerous drug on the market.Because of fears about the liver toxicity of its ... [Published Examiner.com - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 16010) - Meeting

TIME: 8 a.m.EVENT: Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 16010) holds a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee to discuss the safety and efficacy for new drug application ... [Published Pharmacy Choice - Apr 14 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

8 Biotech Events To Anticipate This Year: Part Two

By Brian Nichols :In this article, I am looking at four more events in biotechnology that could spark substantial gains during the remainder of this year. Already, I have covered four such events including upcoming data announcements, product launches, ... [Published BioPortfolio - Apr 08 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

FDA Sets 22 April 2014 For Moxduo® Advisory Committee Meeting

By a News Reporter-Staff News Editor at Pharma Business Week -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced the United States Food and Drug Administration (FDA) has set 22 April 2014 as the date of the Advisory Committee meeting to consider ... [Published 4 Traders - Apr 03 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 2 reports

QRxPharma Limited (QRXPF: OTC Pink Current) | Tier Change

12:00 - QRxPharma Limited ( QRXPF : OTC Pink Current) - Tier Change - The symbol, QRXPF, no longer is classified as Grey Market. As of Mon, Mar 31, 2014, QRXPF resides in the OTC Pink Current tier. You may find a complete list of tier changes at otcmarkets.com ... [Published OTC Markets - Mar 31 2014]
Entities: QRxPharma Limited
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

AMRI Opens Wallet, IDIX To Fight Back, QRxPharma Awaits FDA Panel Verdict

Albany Molecular Research Inc. (AMRI: Quote) has agreed to acquire Cedarburg Pharmaceuticals Inc., a contract developer and manufacturer of technically complex active pharmaceutical ingredients, for $38.2 million in cash.The transaction is expected to ... [Published RTTNews.com - Mar 25 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 5 reports

FDA Sets Date for Moxduo Advisory Committee Meeting

QRxPharma Limited announced today the United States Food and Drug Administration (FDA) has set 22 April 22, 2014 as the date of the Advisory Committee meeting to consider the ... ... [Published Big News Network - Mar 24 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

QRxPharma: Pivotal Catalysts Present Significant Near-Term Upside Potential

By Matt Gravitt:QRxPharma ( OTCQX:QRXPY ) (simply referred to as QRX in this article) is an Australian biotech that you probably haven't heard of much. In fact I didn't know about it until very recently. However when I started to research the company, ... [Published BioPortfolio - Mar 21 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

QRxPharma: Pivotal Catalysts Present Significant Near-Term Upside Potential

SummaryQRXPY has make or break regulatory catalysts occurring within the next 2 months that will bring some much needed attention to an under the radar stock. Their product for pain relief product portfolio has potential to be best in class and previous ... [Published Seeking Alpha - Mar 21 2014]
First reported Mar 17 2014 - Updated Mar 17 2014 - 2 reports

Markets Live: Crimea fears dominate

Mr Joyce's scheduled appearance on Tuesday night comes after he told a separate senate inquiry on Friday that Qantas has set up 250 projects to look at ways it can slash costs by $2 billion over the next three years.Under pressure from unions to reveal ... [Published WA Today - Mar 17 2014]

Quotes

"As previously announced, our PDUFA date is 25 May, 2014 ," said Dr JohnJohn Holaday , Managing Director and Chief Executive Officer, QRxPharma . "We look forward to presenting to the Advisory Committee the Moxduo clinical data as outlined in our New Drug Application highlighting what the Company believes is Moxduo's respiratory benefit from Study 022."
"Moxduo intravenous (IV) is designed to address hospital-based, post-surgical pain. Studies comparing the efficacy and safety of Moxduo have demonstrated that QRxPharma's formulation of Moxduo IV resulted in less drug administered, fewer side effects and offered better pain relief than morphine alone."
"Obviously, there's significant concern that any escalation in tensions within the region could disrupt the flow of grain out of Russian and Ukrainian ports, and therefore contribute to a near-term shortage in grain markets."

More Content

All (27) | News (24) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
"We don't think we need new opioids": An exclus... [Published Examiner.com - Apr 17 2014]
Hidden Australian Life Sciences Growth Stocks R... [Published Seeking Alpha - Apr 17 2014]
FDA to consider morphine-oxycodone combo pill [Published Examiner.com - Apr 15 2014]
Health and Human Services Department (HHS); Foo... [Published Pharmacy Choice - Apr 14 2014]
8 Biotech Events To Anticipate This Year: Part Two [Published BioPortfolio - Apr 08 2014]
8 Biotech Events To Anticipate This Year: Part Two [Published Seeking Alpha - Apr 07 2014]
FDA Sets 22 April 2014 For Moxduo® Advisory Com... [Published 4 Traders - Apr 03 2014]
QRxPharma Limited (QRXPF: OTC Pink Current) | T... [Published OTC Markets - Mar 31 2014]
QRxPharma Limited (QRXPF: OTC Pink Current) | V... [Published OTC Markets - Mar 31 2014]
AMRI Opens Wallet, IDIX To Fight Back, QRxPharm... [Published RTTNews.com - Mar 25 2014]
FDA Sets Date for Moxduo Advisory Committee Mee... [Published Big News Network - Mar 24 2014]
FDA Sets 22 April 2014 For Moxduo® Advisory Com... [Published Nasdaq - Mar 24 2014]
FDA Sets Date for Moxduo Advisory Committee Mee... [Published PharmaceuticalProcessing - Mar 24 2014]
FDA Sets 22 April 2014 For Moxduo® Advisory Com... [Published Benzinga.com - Mar 24 2014]
FDA Sets 22 April 2014 For Moxduo® Advisory Co... [Published TickerTech.com - Mar 24 2014]
QRxPharma: Pivotal Catalysts Present Significan... [Published BioPortfolio - Mar 21 2014]
QRxPharma: Pivotal Catalysts Present Significan... [Published Seeking Alpha - Mar 21 2014]
Markets Live: Crimea fears dominate [Published WA Today - Mar 17 2014]
total comments 39 [Published Sydney Morning Herald - Mar 17 2014]
QRxPharma Completes A$11.6 Million Capital Raising [Published Financial Services - Dec 13 2013]
QRxPharma signs license deal with Teva to comme... [Published Pharmaceutical Business Review - Nov 28 2013]
QRxPharma Announces MOXDUO License Deal In Israel [Published Financial Services - Nov 27 2013]
QRxPharma refiles MOXDUO new drug application w... [Published Pharmaceutical Business Review - Nov 27 2013]
QRxPharma Refiles MOXDUO® New Drug Application ... [Published Financial Services - Nov 26 2013]
DTC - October 24, 2013 - 1822-13 - Depositary F... [Published DTCC - Oct 24 2013]
QRxPharma expands MoxDuo license deal with Aspe... [Published Pharmaceutical Business Review - Oct 16 2013]
US FDA schedules review meeting for QRxPharma's... [Published Pharmaceutical Business Review - Sep 09 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
QRxPharma Completes A$11.6 Million Capital Raising [Published Financial Services - Dec 13 2013]
QRxPharma Announces MOXDUO License Deal In Israel [Published Financial Services - Nov 27 2013]
QRxPharma Refiles MOXDUO® New Drug Application ... [Published Financial Services - Nov 26 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.